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Background: 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used
α-emitters in cancer research. High specific activity radioligands are required for
peptide receptor radionuclide therapy. The use of generators containing less than
222 MBq 225Ac (actinium), due to limited availability and the high cost to produce
large-scale 225Ac/213Bi generators, might complicate in vitro and in vivo applications
though.
Here we present optimized labelling conditions of a DOTA-peptide with an 225Ac/213Bi
generator (< 222 MBq) for preclinical applications using DOTA-Tyr3-octreotate
(DOTATATE), a somatostatin analogue. The following labelling conditions of DOTATATE
with 213Bi were investigated; peptide mass was varied from 1.7 to 7.0 nmol,
concentration of TRIS buffer from 0.15 mol.L-1 to 0.34 mol.L-1, and ascorbic acid from 0
to 71 mmol.L-1 in 800 μL. All reactions were performed at 95 °C for 5 min. After
incubation, DTPA (50 nmol) was added to stop the labelling reaction. Besides
optimizing the labelling conditions, incorporation yield was determined by ITLC-SG and
radiochemical purity (RCP) was monitored by RP-HPLC up to 120 min after labelling.
Dosimetry studies in the reaction vial were performed using Monte Carlo and in vitro
clonogenic assay was performed with a rat pancreatic tumour cell line, CA20948.
Results: At least 3.5 nmol DOTATATE was required to obtain incorporation≥ 99 % with
100 MBq 213Bi (at optimized pH conditions, pH 8.3 with 0.15 mol.L-1 TRIS) in a reaction
volume of 800 μL. The cumulative absorbed dose in the reaction vial was 230 Gy/
100 MBq in 30 min. A minimal final concentration of 0.9 mmol.L-1 ascorbic acid was
required for ~100 MBq (t = 0) to minimize radiation damage of DOTATATE. The
osmolarity was decreased to 0.45 Osmol/L.
Under optimized labelling conditions, 213Bi-DOTATATE remained stable up to 2 h after
labelling, RCP was≥ 85 %. In vitro showed a negative correlation between ascorbic acid
concentration and cell survival.
Conclusion: 213Bismuth-DOTA-peptide labelling conditions including peptide amount,
quencher and pH were optimized to meet the requirements needed for preclinical
applications in peptide receptor radionuclide therapy.
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Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic
and inoperable neuroendocrine tumours (van der Zwan et al. 2015; Bergsma et al.
2012; Bodei et al. 2012). The most common radionuclides used for PRRT include 177Lu
(β−-emitter, T1/2 = 6.71 days, 149 and 497 keV) and
90Y (β−-emitter, T1/2 = 64.1 h, 935
and 2284 keV).
α-Emitters have been demonstrated to offer an additional treatment option for pa-
tients refractory to standard PRRT with β−-emitters or chemotherapy (Kratochwil et al.
2011; Jurcic et al. 1995; Cordier et al. 2010). Moreover, α-particles have short path
length in tissue (~80 μm), sparing non-target tissues from radiation. 213Bi (T1/2 =
45.6 min) is an α-emitter and has been applied in several (pre) clinical research studies
of targeted alpha therapy (TAT) (Kratochwil et al. 2011; Jurcic et al. 1995; Norenberg
et al. 2006; Song et al. 2008; Wild et al. 2011).
PRRT is based on receptor-mediated processes. In order to achieve treatment
success, a sufficient cytotoxic dose of radio-peptide must be delivered to the tar-
geted cells (Konijnenberg 2014). Moreover, the number of receptors available on
the cell membrane is limited, so high specific activity (SA, expressed in MBq per
nmol of peptide) of labelled peptides is advantageous for administration in small
animals e.g. mice (~25 g) (Breeman et al. 2001; Breeman et al. 1995; de Jong et al.
1999). Besides high SA, other requirements for preclinical applications include high
stability of the radio-peptide at physiological conditions in vitro (~0.3 Osmol.L−1,
pH ~7.4) and in vivo. In additional, a high osmolarity of the drug-containing solu-
tion is inconsistent with maintenance of physiological conditions for in vitro and
in vivo applications.
Due to the limited availability and the high cost to produce large-scale 225Ac/213Bi
generators, preclinical studies with 213Bi are often being performed using relatively low
activity generators (e.g. 222 MBq 225Ac). Under these conditions, the standard clinical
labelling procedure for 213Bi, which was designed for high activity generators (up to
4 GBq) with a reaction volume of 2 mL at > 0.7 Osmol.L−1 (Kratochwil et al. 2014),
probably needs to be adjusted. Therefore, the labelling conditions for preclinical appli-
cations required modifications.
In this study, we systematically studied the consequences using the somatostatin
analogue [DOTA0, Tyr3]-octreotate (DOTATATE) as a model for optimizing label-
ling conditions of 213Bi for preclinical applications, starting from the standard la-
belling protocol.
Herein we varied the labelling conditions such as peptide amount, quencher and
pH. The stability of the labelled peptide and the radiochemical purity (RCP) was
monitored up to 2 h after labelling. The absorbed dose rates of 213Bi, 213Po, 209Tl
and 209Pb (mGy.s−1) as function of reaction volume were calculated. The use of
the absorbed dose rate is investigated as a possible surrogate indicator for the
ionization probability and consequential radiolysis to the peptide in the reaction
vial. And lastly, in vitro clonogenic assay was performed to investigate the influ-
ence caused by labelling conditions used.
The objective of this study was to establish a practical, ready to use, and reproducible
labelling procedure of 213Bi-DOTATATE to meet the constraint for the use of peptide
as radiopharmaceutical for preclinical applications.
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213Bi-elution
The 225Ac/213Bi generator (222 MBq) was supplied by the Institute for Transuranium
Elements (ITU), Germany. Prior to elution, the column was rinsed with diluted HCl
(0.01 mol.L−1). 213Bi was eluted from the 225Ac/213Bi generator by NaI/HCl (0.1 mol.L
−1/0.1 mol.L−1) in a volume of 600 μL. After elution the column was rinsed and stored
with diluted HCl (0.01 mol.L−1) (Morgenstern et al. 2012).Standard protocol radiolabelling of 213Bi-DOTATATE
DOTATATE (DOTA-DPhe-Cys-Tyr-DTrp-Lys-Thr-Cys-Thr, Mw 1436 g/mol) was pur-
chased from BioSynthema (St. Louis, MO, USA). All chemicals were purchased from
Sigma-Aldrich (Zwijndrecht, the Netherlands).
The following standard labelling protocol was applied: 213Bi (600 μL) was added to
DOTATATE (7.0 nmol), TRIS buffer (0.34 mol.L−1), ascorbic acid (71 mmol.L−1) and
MilliQ water in a final volume 800 μL at pH 8.7. The reaction was incubated for 5 min
at 95 °C. The radionuclide incorporation reaction was halted by cooling the mixture for
2 min in ice and through the addition of 50 nmol diethylenetriaminepentaacetic acid
(DTPA, Erasmus MC Pharmacy) to chelate any unbound or “free” 213Bi.Labelling optimization for preclinical studies
Standard labelling protocol was used as described above, while varying the following
conditions:
1. Peptide mass; labelling was performed with 1.7, 3.5 and 7.0 nmol DOTATATE .
2. pH dependence study; 7.0 nmol DOTATATE was labelled in a reaction containing
71 mmol.L−1 ascorbic acid and 0.15 mol.L−1 and 0.34 mol.L−1 TRIS buffer.
3. Quencher dependence study; in absence of ascorbic acid and 0.1, 0.3, 0.9, 2.6, 7.9,
24 and 71 mmol.L−1 ascorbic acid.Quality control of radiolabelled peptide
The quality control of labelled peptides was determined by ITLC-SG (instant thin layer
chromatography silica gel, Varian) and HPLC (high performance liquid chromatography).
Incorporation yield (expressed as mean ± SD) was determined by ITLC-SG using so-
dium citrate (0.1 mol.L−1, pH 5) as mobile phase. The 213Bi activity was determined by
HPGe detector with a pulse height multichannel analysis (MetorX, Goedereede, The
Netherlands and Software Genie 2000 Canberra) at fixed geometry, all measurements
were performed for the 440 keV γ-emission by 213Bi with a yield of 0.261 per decay.
The counting efficiency of the HPGe detector at 440 keV γ-emission was determined
using a known amount of 225Ac activity provided and calibrated by ITU, Germany
(Morgenstern et al. 2012; Ma et al. 2001; McDevitt et al. 1999).
The RCP (expressed as percentage ± SD intact radio-peptide of interest, compared to
other detectable radioactive compounds in the same analysis) and stability of the la-
belled peptide as function of time were determined by HPLC. HPLC-grade methanol
and trifluoracetic acid (TFA) were purchased from Mallinckrodt Baker (Deventer, the
Netherlands). The HPLC system (Waters 2695 separation module, Alliance, Waters,
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ters 2996 photodiode array detector (Waters, Etten-Leur, The Netherlands), radiometric
sodium iodide detector (Canberra, Canberra, Genie 2000) and symmetry C18 5 μm col-
umn, 4.6 mm ×250 mm (Waters, Etten-Leur, The Netherlands). The mobile phase con-
sisted of buffer A (0.1 % TFA in water) and buffer B (Methanol). The gradient used for
the analysis was as described earlier (de Blois et al. 2011). The retention times of the
unlabelled DOTATATE and 213Bi-DOTATATE were 12.0 ± 0.3 min and 13.0 ± 0.3 min,
respectively.Dosimetry model of 213Bi exposure in reaction vials
The degradation of radiopharmaceuticals by radiolysis is dependent on the amount of
energy absorbed within the ligand. Most of the α-particle energy emitted by 213Bi and
its daughter 213Po will be absorbed within the reaction vial with the 213Bi-labelled com-
pound, as their particle ranges in water are smaller than the vial dimensions. The en-
ergy emitted by the α- and β−-particles from 213Bi itself and its daughters 209Tl
and 209Pb, however, will not be completely absorbed within the small vials. The ac-
tivity as a function of time for 213Bi, 213Po, 209 Tl and 209Pb was calculated by the
Bateman equations, see Additional file 1: Equation 1. The β−-emission spectra are
summarized in Table 1 together with their ranges in water, from the NIST Star
database (http://www.nist.gov/pml/data/star/; assessed 27-11-‘15). The α-particle en-
ergies from 213Bi and 213Po are also indicated with their projected ranges as calcu-
lated with the Stopping and Range of Ions in Matter (SRIM version 2013.00
software; www.SRIM.org). The recoil energies from the α-particle emissions are
112 keV (213Bi) and 160 keV (213Po) (Eckerman KF MIRD2008 2999).
Radiation transport was calculated for 213Bi containing liquid inside reaction vials to
determine the absorbed energy and absorbed dose to the hot liquid. The Monte Carlo
codes MCNP5 (MCNP Team The Monte Carlo codes MCNP52005 2999) and MCNPX
(Hendricks JS MCNPX Extensions Version 2 5 02005 2999) were used for the calcula-
tions. Calculations for the α-particles from 213Bi and 213Po were performed with
MCNPX using the α-particle energies listed in Table 1. The β−-spectra and low-energy
internal conversion and Auger electron spectra for 213Bi, 209Tl and 209Pb from MIRD
Radionuclide data and decay schemes book (Eckerman KF MIRD2008 2999) were usedTable 1 α- and β-particle emissions by 213Bi and its daughters, emission abundances per decay of
213Bi or daughter nuclide and energies are from the MIRD Radionuclide data and decay schemes
book (Eckerman, 2008). Particle ranges (mm) in water were determined from the NIST Star
database (electrons) and with the SRIM code (α-particles). Abundance (Ab.) is expressed in %
decay and energy (E) in MeV
α-particles Ab. (%/decay) E (MeV) range (μm)
213Bi 1.94 5.87 46.47
213Po 100 8.38 81.75
β-particles Ab. (%/decay) Emean (MeV) range (mm) Emax (MeV) range (mm)
213Bi 97.91 0.434 1.45 1.422 6.65
209Tl 100 0.655 2.55 1.944 9.48
209Pb 100 0.197 0.44 0.644 2.49
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lated so as to be uniformly distributed within a conical reaction vial with isotropic dir-
ection emission. All physics processes were taken into account by choosing either the α
(MODE A) or the photon–electron mode (MODE P E) and the default PHYS cards
with the default cut-off energy at 1 keV for electrons and photons and 4 MeV for α-
particles. The *F8 tally determined energy absorption within the hot reaction fluid. Suf-
ficient particle histories (NPS) were used to reduce the variation in the data to be less
than 5 % for most cases; NPS was set to 1 × 107 particles. A conically shaped 1 mL re-
action vial was modelled with various volumes of radioactive fluid inside the vial. The
MCNP-model geometry for a vial containing 0.8 mL liquid is shown in Fig. 1. The la-
belling volumes were modelled: 10, 50, 100, 200, 400 and 800 μL by adjusting the reac-
tion fluid level accordingly. Average dose rates were determined in the vial volume.In vitro clonogenic assay
For in vitro clonogenic assays the CA20948 cell line (derived from a rat pancreas
tumour at our institute Erasmus MC) was used. CA208948 is a rat pancreatic tumour
cell line with relative high expression of somatostatine receptor type 2 (SSTR2), and
was cultured in DMEM supplemented with 10 % fetal calf serum (FBS, Gibco, Life
technologies). Cells (500 cells/well) were seeded in 6-wellplates pre-coated with poly-l-
lysine 24 h before exposure to the compounds used for labelling, except for peptide
and 213Bi. For clonogenic assay, 400 μL of standard labelling procedure was used, and
diluted in 8 mL incubation medium containing 30 mmol.L-1 HEPES and 0.25 % BSA.
The concentration of TRIS, ascorbic acid, NaI, HCl and DTPA corresponded to 16, 3.4,i.d. 6.2 mm
Fig. 1 MCNP geometry input for 1 mL reaction vial with 0.8 mL radioactive fluid (in blue), water with
density 1 g/mL. The vial wall (in grey) had a thickness of 0.65 mm and was polyethylene with
density 0.9 g/mL
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for 1 h at 37 °C in a humidified atmosphere of 5 % CO2 and 95 % air. Untreated
CA20948 cells were used as control. After 1 h, incubation medium containing labelling
compounds was removed from cells, cells were washed twice with PBS and incubated
with culture medium containing 10 % FBS for 12 days. Every 2 or 3 days, culture
medium was replaced by fresh medium. At day 12, colonies were fixed with 100 %
ethanol and stained with hematoxyline. Survival colonies were counted and the survival
CA20948 was determined. Clonogenic assay with CA20948 as function of ascorbic acid
was also performed with the method described above.Results
Labelling
The standard labelling protocol 213Bi-DOTATATE resulted in an incorporation > 99 %
and a RCP > 85 % at pH 8.7 for up to 2 h after labelling. The calculated osmolarity of
the labelling using the standard procedure was 0.7 Osmol.L−1.
Labelling with 1.7 nmol DOTATATE in 800 μL resulted in low incorporation of 6 ±
4 % and poor RCP of 5 ± 5 % (median: 6.9 % (range: 0–8.6 %)), see Fig. 2. A high in-
corporation and high RCP were found when labelled with 3.5 nmol (incorporation was
99 ± 1 %, RCP was 89 ± 4 %) and 7.0 nmol peptide (incorporation was 99 ± 1 %, RCP
was 88 ± 6 %).
Reducing the amount of TRIS buffer in the labelling did not show an effect on the in-
corporation of the labelled compound, incorporation of > 99 % and a RCP of > 85 %
were found for labelling with 0.15 mol.L−1 and 0.34 mol.L−1 TRIS, corresponding to
pH 8.3 and 8.7, respectively.
After labelling in the presence of ascorbic acid under the standard procedure, an in-
corporation of >99 % and a RCP of > 85 % were found, Fig. 3a. Labelling in absence of
ascorbic acid however showed a high incorporation of 99 ± 1 % but at poor RCP, < 5 %
213Bi-DOTATATE remained intact after labelling, as shown in the HPLC chromato-
gram, Fig. 3b.Fig. 2 The incorporation (%) of 213Bi-DOTATATE 71 ± 28 MBq determined by ITLC analysis as function of
peptide amount in a reaction volume of 800 μL. An S-shaped cureve has been fitted through the data with
an incorporation of 50 % at 2.4 ± 0.09 nmol and a slope of 0.25 ± 0.03 nmol peptide, n≥ 3
Fig. 3 HPLC chromatogram of 213Bi-DOTATATE in presence a and absence b of ascorbic acid during
labelling (n≥ 3). Peak A; RT = 13.0 min and peak B; RT = 16.3 min. The y-axis represents the detected
radioactive signals (mV) and x-axis represents the RT in minutes
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ascorbic acid was performed, it showed that at least 0.9 mmol.L−1 ascorbic acid
was required to maintain high incorporation and high RCP (>85 %), The labelled
peptide showed a RCP > 85 % up to 2 h after labelling. A RCP of 75 ± 8 %, 83 ±
1 %, 87 ± 1 %, 86 ± 1 %, 86 ± 1 %, 87 ± 1 %, 88 ± 0.4 % were found by addition of
0.1 mmol.L−1, 0.3 mmol.L−1, 0.9 mmol.L−1, 2.6 mmol.L−1, 7.9 mmol.L−1, 24 mmol.L−1 and
71 mmol.L−1 ascorbic acid, respectively. Addition of less than 0.9 mmol.L−1 ascorbic acid
resulted in high incorporation directly after radiolabeling, however the RCP decreased
over time, see Fig. 4.0 50 100 150
50
75








Fig. 4 Stability as function of time of 213Bi-DOTATATE with different concentration ascorbic acid added
during labelling, y-axis is RCP expressed in mean percentage ± SD and x-axis time in minutes after
labelling (n≥ 3)
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0.15 mol.L−1 TRIS buffer containing 2.6 mmol.L−1 ascorbic acid in a reaction volume
of 800 μL with 71 ± 28 MBq 213Bi, with a calculated osmolarity of 0.45 Osmol.L−1.Dosimetry
The absorbed fraction of energy from the α-particles from 213Bi was almost
complete within the reaction fluids, 98.9 % for the 10 μL reaction volume and fur-
ther rose to 99.7 % for 800 μL. The higher energy α-particles from 213Po showed a
little more energy transfer to the vial wall; 97.2 % was absorbed in 10 μL and
99.2 % in 800 μL. The absorbed dose rate caused by 213Bi, 213Po, 209 Tl and 209Pb
were predominantly contributed by the α-particles from 213Bi and 213Po, see Fig. 5a.
The β−-particles and low energy electrons were less absorbed within the reaction
fluid, e.g. the absorbed fraction of energy by β−-particles from 213Bi ranges from
44 % (10 μL) to 77 % (800 μL). The relative contribution of the β−-particles to the
total 213Bi S-value thus raised from 58 to 70 %. The absorbed dose rate caused by
α-particles (initially 165 mGy.s−1) continued to be high compared to the absorbed
dose rate of β−-particles (initially 7 mGy.s−1), see Fig. 5b.
Based on the absorbed dose rate, see Table 2, the estimated absorbed dose for 100 MBq
was > 230 Gy at 30 min in a reaction vial containing 800 μL hot reaction fluid. The
absorbed dose was predominantly caused by the decay of α-particles, see Fig. 5b.Clonogenic assay
In all cells treated in present of ascorbic acid (corresponding to 3.4 mmol.L−1 in incu-
bation medium), a significant decrease of survival was found compared to control cells,
P < 0.05, see Fig. 6. Control cell survival was 100 % with a standard deviation of 12 %.
The mean cell survival ± SD of CA20948 after exposure to ascorbic acid or in combin-
ation with TRIS, NaI, HCl and DTPA was listed in Table 3. The concentration of TRIS,
NaI, HCl, and DTPA in incubation medium was 16 mmol.L−1, 3.6 mmol.L−1,
3.6 mmol.L−1 and 6.1 × 10−3 mmol.L−1, respectively.
Reducing the concentration of ascorbic acid during the labelling, resulted in an in-
























































Fig. 5 Time-integrated activity of 213Bi, 213Po, 209Tl and 209Pb determined by Bateman equations a and the
resultant total absorbed dose rate b as a function of time, see Table 2. The majority of the absorbed dose
rate (96 % at 60 min) is caused by the α-particles from 213Bi and 213Po
Table 2 Absorbed dose rates per unit activity (S-values, in mGy/MBq.s) in the reaction fluid for
different volumes of 213Bi, 213Po, 209Tl and 209Pb. The different contributes to the S-value (α, β, low
energy electrons and γ-rays) are indicated separately
213Bi 10 μL 50 μL 100 μL 200 μL 400 μL 800 μL
5.97 MeV α 1.94 0.39 0.19 0.097 0.049 0.024
β-particles 2.98 0.80 0.44 0.24 0.13 0.066
Auger + IC e− 0.20 0.048 0.026 0.013 0.0067 0.0034
γ-rays 0.0054 0.0019 0.0012 0.0007 0.0005 0.0003
Total 5.12 1.24 0.67 0.35 0.18 0.094
213Po
8.38 MeV α 130 26.4 13.3 6.6 3.3 1.7
209Tl
β-particles 3.17 0.94 0.55 0.30 0.17 0.08
Auger + IC e− 0.36 0.08 0.04 0.02 0.01 0.01
γ-rays 0.04 0.02 0.01 0.01 0.00 0.00
Total 3.57 1.03 0.60 0.33 0.18 0.09
209Pb
β-particles 2.33 0.53 0.28 0.14 0.07 0.04
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A cytotoxic dose within the tumour cells is required to cause a therapeutic effect of
TAT, when using a receptor-mediated process as dose delivery method. In the clinical
situation using β−-emitters, this cytotoxic dose is in the order of 200 Gy for neuroendo-
crine tumours (Ilan et al. 2015; Pauwels et al. 2005) and in the preclinical situation this
dose is in the order of 70 Gy for cure of CA20948 (rat pancreatic) tumour (Verwijnen
et al. 2004). The limited number of receptors available on the cell membrane and rela-













































































Fig. 6 Survival (%) ± SD of CA20948 after exposure to the compounds used in standard labelling procedure,
n = 3. Concentration in incubation medium was; [TRIS] = 16 mmol.L−1, [AA] = ascorbic acid, 3.4 mmol.L−1,
[NaI] = 3.6 mmol.L−1, [HCl] = 3.6 mmol.L−1 and [DTPA] = 6.1 × 10−3 mmol.L−1
Table 3 CA20948 clonogenic survival in mean percentage ± SD after exposure to ascorbic acid or
in combination with TRIS, NaI, HCl and DTPA, n = 3. Concentration in incubation medium was;
[TRIS] = 16 mmol.L−1, [AA] = ascorbic acid, 3.4 mmol.L−1, [NaI] = 3.6 mmol.L−1, [HCl] = 3.6 mmol.L−1
and [DTPA] = 6.1 × 10−3 mmol.L−1
Compounds Survival %
AA 11 ± 1
TRIS + AA 1 ± 1
NaI + HCl + AA 27 ± 5
TRIS + NaI + HCl + AA + DTPA 1 ± 1
AA + NaI 11 ± 4
AA + HCl 12 ± 7
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in a preclinical setting include a low injection volume, physiologic osmolarity, high SA,
and suitable stability. Labelling with a radionuclide generator yielding relatively low
radioactivity is a barrier for high SA radiolabelling.
The most commonly techniques used to increase the SA are purification of the
elution by ion-exchange chromatography or by radiolabelling using fractionated
elution to reduce the reaction volume which may improve the reaction kinetics.
This may allow high incorporation yield with lower peptide amounts and thus in-
crease the SA of the radio-peptide. To mimic this concept, 213Bi-DOTATATE label-
ling was performed with half of the elution volume to a reach lower reaction
volume (total 400 μL), high incorporation yield was achieved even at reduced
amount of peptide, e.g. 1.7 nmol (data not shown).
The most practical method to achieve high SA radiolabelling for preclinical applica-
tions is the use of a higher activity 225Ac/213Bi generator to accomplish the require-
ments needed for preclinical applications. Purification, e.g. by HPLC or solid phase
extraction, might increase the SA. However, introduction of an extra purification step
also increases the time interval prior to injection and thus reduces the 213Bi radioactiv-
ity. Moreover, HPLC purification often introduces organic compounds e.g. methanol or
acetonitrile into the radiolabelling, which might be harmful to animals and limit further
translation to clinical studies.
We found a correlation of ascorbic acid on cell survival; at high concentration of as-
corbic acid used for labelling (71 mmol.L−1, corresponding to 3.4 mmol.L−1 in incuba-
tion medium), a significant reduction of cell survival was observed. A lower reduction
of cell survival was found with only or in combinations with NaI, HCl, TRIS and DTPA
compared to control cells, probably caused by the high osmolarity of NaI, HCl, TRIS or
Zn-depletion to cells by DTPA (Cho et al. 2007), however this reduction was not
significant. Ascorbic acid, functioning as pro-oxidant, is known to be selectively toxic,
especially in vitro to certain type of tumour cells at high concentration (Park 2013). C18
solid phase extraction can be an option to prevent this by removing ascorbic acid from
the labelling reaction. However, radiolysis continues to occur after labelling, and re-
moving ascorbic acid might increase peptide damage caused by radiolysis. After opti-
mizing the labelling conditions, the concentration of ascorbic acid used for labelling
(2.6 mmol.L−1, corresponding to 0.13 mmol.L−1 in incubation medium) did not










Fig. 7 Survival (%) ± SD of CA20948 as function of concentration of ascorbic acid in DMEM incubation
medium containing 30 mmol.L-1 HEPES and 0.25 % BSA (total volume was 8.4 mL), n = 3
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formed and no purifications steps were required for further in vitro and in vivo preclin-
ical applications.
In theory, one DOTA-peptide molecule can incorporate one atom 213Bi, thus at a
molar ratio of 1 metal vs DOTA, under ideal condition the maximum theoretical SA
will be 155 GBq 213Bi /nmol DOTA-peptide. In a study investigating the highest achiev-
able SA, 7.0 nmol DOTATATE was labelled with different mole ratios 209/213Bi using
the standard labelling procedure. At mole ratio of 0.6 209/213Bi vs DOTATATE, the in-
corporation was ≥ 99 %. At mole ratio > 0.6, the incorporation started to decline, pos-
sibly caused by the presence of other cations (derived from decay product of 213Bi,
quencher, buffer, elution solution) in the labelling reaction which interfered with the in-
corporation of 213Bi into DOTA-moiety (Breeman et al. 2005; Zhernosekov et al. 2007).
In theory, a SA of 93 GBq/nmol DOTATATE (at mole ratio 213Bi 0.6) can be achieved
under these labelling conditions.
Radiolabelling of 213Bi is less pH-dependent (in the range tested) as is the case of
111In and 177Lu with formation of insoluble 111InOCl or 177LuOCl (Breeman et al.
2003). Radiolabelling with 213Bi can be performed at pH values ranging from 4.0 to 10
(Norenberg et al. 2006; Hassfjell et al. 2003; Le Gac et al. 2011), due to the formation
BiI4-/BiI5
2− after elution with 0.1 M/0.1 M HCl/NaI (Morgenstern et al. 2012). However,
deprotonation of the carboxyl group of the DOTA appears faster at higher pH and
resulting in more rapid radiolabelling kinetics (Wu et al. 1997; Szilagyi et al. 2000).
In this study, we highlighted that ITLC-SG alone as quality control is not sufficient,
see labelling in absence and presence of ascorbic acid. HPLC provides beside the in-
corporation yield also information of peptide damage caused by α-track or radiolysis.
The formation of free radicals is dependent on the type of radiation, the amount radio-
activity present in the reaction mixture and on the duration of exposure, all of which
have been shown to induce radiation damage of the peptide. Quenchers such as genti-
sic acid in combination with ascorbic acid and ethanol are often used to prevent radiol-
ysis in radiolabelling with 111In or 177Lu (de Blois et al. 2012). Radiolysis leads to
damage of peptide and will decrease the RCP.
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direct radiation damage from the high LET α-particle tracks (Deutsch 1998). Stanton
et al. observed more biological efficacy on SV40 viral DNA in vitro caused by low LET
compared to high LET and Sugo et al. demonstrated less degradation of TODGA, a tri-
dentate complexing agent, after irradiation with helium ion beam than that by that of
γ-ray irradiation (Sugo 2009; Stanton et al. 1993). Since the activated radicals are
formed along the α-particle tracks and therefore decreasing the probability for damage
by both the direct and the radical induced effect in the reaction solution, thus a lower
amount of quenchers is required to prevent radical damage to the peptide. In our case,
ascorbic acid alone showed sufficient protection capacity to prevent damage to the pep-
tide, so no other quenchers were introduced to the labelling, also to prevent further in-
crease of the osmolarity. Higher osmolarity would require further diluting of the
injection matrix for small-animals applications, leading to lower radioactivity injections
for effective TAT in small animals.
Here we present detailed results obtained with MCNP calculations of the absorbed
dose of 213Bi in the reaction vial. The calculated absorbed dose is an average absorbed
dose estimated in a vial of 800 μL, mostly caused by α-particles, but also including
doses from β−-particles and γ-rays emitted by the decay daughters of 213Bi. As shown
in Fig. 4, 0.9 mmol.L−1 ascorbic acid was required to protect the peptide in a vial con-
taining 71 ± 28 MBq in 800 μL, with an absorbed dose of ~200 Gy. At higher radioac-
tivities of 213Bi or smaller reaction volumes, more ascorbic acid was required to protect
the peptide, since the absorbed dose in the reaction vial increased and formation of
radicals also increased. These doses are much lower than the absorbed doses consid-
ered to cause radiation damage in DTPA and TODGA, which are in the order of
100 kGy (Sugo 2009; Stanton et al. 1993). The main sensitive region for radiation dam-
age will therefore be in the DOTATATE’s disulfide bond and its other ionized parts, as
the DOTA cage may be considered not to be damaged at the “low” absorbed doses
considered.
The activation energy for the DOTA ring inversion process is in the order of 65 kJ/
mol (Lima et al. 2015). The initial dose rate by the α-radiation in the vial with
100 MBq 213Bi amounts 165 mGy/s, which corresponds to an absorbed energy rate
of 0.13 mJ/s in 800 μL with 7 nmol compound, or 19 kJ/mol.s. This indicative cal-
culation shows that the momentary dose rate is on average not energetic enough
to create configuration changes within the DOTA ring. The energy of 65 kJ/mol is
reached within 3.5 s.
Stability, incorporation yield and SA of 213Bi-labelled peptides are influenced by
the affinity/stability of the metal-chelator complex, radiolysis or by the recoil effect
both during and after labelling. High LET α-particles cause reactive hydrogen radi-
cals in an aqueous environment (Bibler 1972). These radicals damage the peptide,
which can lead to losses of affinity of the peptide to its receptor. The relative high
recoil energy of 213Po, 160 keV, is a critical challenge for the choice of chelator,
since complexation of metal and chelator is dependent on the binding energy. This
complex should remain stable until reaching the targeted receptor. DOTA (with a
Log K of 30.3) is not considered to be the most suitable chelator for 213Bi, due to
relative poor labelling kinetics compared to derivatives of DTPA, e.g. CHX-A-
DTPA (Brechbiel 2001; Stavila et al. 2006). Nevertheless, we demonstrated that
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time of 5 min. Furthermore, under optimized radiolabelling conditions, the label-
ling remained stable up to 2 h after labelling.
Conclusion
The optimized 213Bi labelling conditions demonstrated to be suitable for labelling of
DOTATATE and proofed ready-to-use for preclinical applications. The labelling pro-
cedure presented herein resulted in high incorporation yield, high RCP and high stabil-
ity up to 2 h after labelling. The addition of quenchers such as ascorbic acid during
labelling appeared essential for the protection of the peptide, since the absorbed dose
rate within the reaction was high; > 165 mGy.s−1 with 100 MBq of 213Bi.
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